Home › Gastroparesis › NCT04208828

IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy

Who can join

Ages 12 to 90 · All sexes

Inclusion Criteria: Patient with otherwise refractory symptoms of gastrointestinal (GI) motor disorders.

\-

Exclusion Criteria: Inability to receive intravenous immunoglobulin.

\-

About the study

Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions/ Some of these patients have serologic and/or endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.

Sponsor: University of Louisville · Participants: 400 · Started: Jan 2, 2020

Contact the study team

• Thomas L Abell, MD · Phone: (502)852-6991

Official record on ClinicalTrials.gov — NCT04208828

Locations in the U.S.

Conditions

• Gastroparesis
• Nausea and Vomiting
• Abdominal Pain

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.